Real-world study of secukinumab for HS in Canada
Part of Infections, Skin clinical trials.
This study looks at how well secukinumab (Cosentyx) works in real life for people with moderate-to-severe hidradenitis suppurativa (HS) in Canada. If you're just starting this treatment, researchers want to track your progress and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) diagnosed with moderate-to-severe hidradenitis suppurativa (HS).
- You are starting secukinumab (Cosentyx) for the first time, or started it within the last 7 days.
- You have not taken secukinumab before (for more than a week).
- You can understand and give consent in Canadian English or French.
- You have no medical conditions or allergies that would make secukinumab unsafe for you (as decided by your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
This study looks at people with moderate to severe hidradenitis suppurativa (HS) who start treatment with secukinumab early. It aims to see how well the treatment works and how it affects the condition over time.
This study looks at whether secukinumab (a drug used for hidradenitis suppurativa) affects heart health in people who also have high heart risk or heart plaque. You'd receive the standard care with secukinumab and undergo special heart imaging to see how the drug affects your arteries.
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.